Mackenzie Financial Corp Novavax Inc Transaction History

Mackenzie Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$36.28 - $75.29 $271,446 - $563,319	-7,482 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$69.73 - $142.9 $489,922 - $1 Million	-7,026 Reduced 48.43%	7,482 $551,000
Q4 2021 Feb 14, 2022	SELL	$134.56 - $217.97 $554,925 - $898,908	-4,124 Reduced 22.13%	14,508 $2.08 Million
Q3 2021 Nov 08, 2021	BUY	$177.8 - $270.58 $168,910 - $257,050	950 Added 5.37%	18,632 $3.86 Million
Q2 2021 Aug 11, 2021	BUY	$121.0 - $257.67 $521,147 - $1.11 Million	4,307 Added 32.2%	17,682 $3.75 Million
Q1 2021 May 14, 2021	BUY	$112.98 - $319.93 $1.51 Million - $4.28 Million	13,375 New	13,375 $2.43 Million

292

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $629M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.